Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
Who is this study for? Patients with Uveal Melanoma
What treatments are being studied? Blood Test
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patient aged of 18 years or more.
• Patient with uveal melanoma with high metastatic relapse risk defined as :
‣ T2b/c/d ou ≥ T3,
⁃ or chromosom 3 or chromosom 8 abnormality by CGH array.
• Completion of treatment of the primary tumor ≤ 2 months.
• Patient able to comply with the schedule of visits and blood samples of the study.
• Signed informed consent form or legal representative.
Locations
Other Locations
France
Institut Curie
RECRUITING
Paris
Contact Information
Primary
Sophie Piperno-Neumann, MD
sophie.piperno-neumann@curie.fr
01 44 32 46 72
Backup
Marie-Emmanuelle Legrier, PhD
drci.promotion@curie.fr
01 56 24 56 49
Time Frame
Start Date: 2020-07-08
Estimated Completion Date: 2037-07-07
Participants
Target number of participants: 700
Treatments
Other: Patients with uveal melanoma
High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. For enucleated patients, a blood sample is required according to the study schedule.
Related Therapeutic Areas
Sponsors
Leads: Institut Curie